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P+ARMACEUTICAL 'RU* PRICIN* T+E
INTERNET A6 A 6OLUTION FOR T+I6
+EALT+ I66UE TURNE' FINANCIAL I66UE
AB6TRACT
Over the course of five decades, American annual expenditure on
pharmaceutical drugs has increased by more than $350 billion. This drastic
increase has led many patients to struggle to afford their necessary, and
potentially life-saving, medications. Today’s high pharmaceutical prices
are largely due to the fact that name-brand drug manufacturers have few
restrictions on how much they can charge for their products. Additionally,
name-brand manufacturers are able to monopolize the manufacture of their
drugs because patent laws prevent other manufacturers from using the
formula of these drugs for two decades. To combat these high prices, this
Note proposes a partnership between telemedicine companies and online
pharmacies that promotes the prescription of cheaper, generic-brand
drugs. By combining the cheaper, mobile services of telemedicine with
generic-brand drugs offered by online pharmacies, this partnership can
increase access and quality of healthcare while driving down price
INTRO'UCTION
³You are VucK a moron´
1
7KiV waV tKe reVponVe from tKe TueVtionaEle
KeGJe funG manaJer, anG now conYicteG felon, Martin 6Kkreli,
2
wKen Ke
waV aVkeG aEout acTuirinJ tKe riJKtV to market 7Kiola

anG increaVinJ itV
price from leVV tKan 1 per pill to 0 per pill
4
$ltKouJK pKarmaceutical
GruJ priceV KaYe Eeen riVinJ for GecaGeV, tKe iVVue of outraJeouVly
oYerpriceG GruJV waV not tKruVt into tKe VpotliJKt until 6Kkreli KikeG
7Kiola¶V price Ey 2000

:Kile 6Kkreli¶V e[orEitant price Kike may Ee an
³outraJeouV´ outlier, it KelpV VKeG liJKt on tKiV comEineG KealtK anG
financial iVVue

7Ke 7Kiola Vituation e[poVeV tKat pKarmaceutical
1 JoKn Carroll, Why Would Martin Shkreli Hike an Old Drug Price by 5000%? Only a
‘Moron’ Would Ask, F,ERCEB,O7EC+ 6ept 20, 201, 120 3M, KttpVwwwfierceEiotecKcom
EiotecKwKywoulGmartinVKkreliKikeanolGGruJpriceEy000onlyamoronwoulGaVk
2 MattKew +erper, You Hate Martin Shkreli. That’s Sort of a Problem, FORBE6 Mar 9,
201, KttpVwwwforEeVcomViteVmattKewKerper201009youKatemartinVKkrelitKatV
VortoftKeproElemEcae2af
 ³7+,OL$ taEletV iV a preVcription meGicine ,t iV uVeG in comEination witK KiJK fluiG
intake, alkali low aciG, anG Gietary cKanJeV to Kelp preYent tKe formation of one type cyVtine of
kiGney VtoneV in certain aGult anG peGiatric patientV tKat weiJK at leaVt 44 pounGV 20 kJ anG wKo
Go not reVponG to tKeVe meaVureV alone´ How Does THIOLA Work?, 7+,OL$COM,
KttpVwwwtKiolacomaEouttKiola laVt YiViteG 6ept 1, 2019
4 Carroll, supra note 1
 LyGia RamVey, The CEO Who Jacked up the Price of a Drug by 5,000% Has Done This
Before, BU6 ,N6,'ER 6ept 2, 201, 222 3M, KttpVwwwEuVineVVinViGercommartinVKkreli
KiVtoryofpriceKikeV2019
. Id.
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companieV retain tKe aEility to raiVe priceV in a manner Vimilar to 6Kkreli
EecauVe Ke waV conYicteG of VecuritieV cKarJeV, none of wKicK KaG anytKinJ
to Go witK KiV price KikeV

6ome VolutionV, VucK aV tranVparency leJiVlation,
KaYe Eeen enacteG in orGer to promote price reGuction, Eut only minimal
cKanJe KaV Eeen oEVerYeG EecauVe tranVparency leJiVlation anG otKer
VolutionV KaYe encountereG VucceVVful puVKEack from tKe pKarmaceutical
inGuVtry

7KiV Note arJueV tKat comEininJ tKe JrowinJ marketV of telemeGicine
anG online pKarmacieV can increaVe meGicinal Tuality anG acceVV, wKile
GriYinJ Gown tKe coVt of pKarmaceutical GruJV ,n otKer worGV, tKe
partnerVKip Eetween tKe two marketV will increaVe GruJ pricinJ competition
wKile proYiGinJ Jreater acceVV to Tuality care anG a wiGer ranJe of cKeaper,
offEranG pKarmaceuticalV, tKuV GriYinJ Gown GruJ pricinJ
3art , of tKiV Note proYiGeV a Erief KiVtory of pKarmaceutical pricinJ in
tKe UniteG 6tateV, followeG Ey 3art ,,¶V reYiew of preYiouVly propoVeG
VolutionV to $merica¶V KiJK GruJ priceV 3art ,,, will proYiGe a GeVcription
of telemeGicine, online pKarmacieV, anG UniteG 6tateV internet uVe
$GGitionally, 3art ,,, GetailV tKe EuVineVV Vtructure of tKiV Note¶V propoVeG
partnerVKip 3art ,V will tKen tackle tKe moVt preVVinJ leJal iVVueV facinJ
tKe propoVeG comEination, VucK aV $ntitruVt anG priYacy lawV LaVtly, 3art
V GiVcuVVeV Ro, a VmallVcale telemeGicineonline pKarmacy, in orGer to
Vupport tKe YiaEility of tKiV Note¶V propoVeG Volution
I BACK*ROUN'
3reVcription GruJ VpenGinJ in tKe UniteG 6tateV KaV Eeen on tKe riVe for
nearly Vi[ GecaGeV, witK tKe moVt ViJnificant increaVeV GurinJ tKe paVt
twenty yearV
9
,n 190, for e[ample, tKe UniteG 6tateV e[penGiture on
preVcription GruJV waV 2 Eillion
10
By 1990, $merican GruJ e[penGiture
increaVeG to 40 Eillion, anG tKen increaVeG furtKer to 20 Eillion Ey
200
11
7Ke current proMection for 2019 iV 0 Eillion
12
'ruJ pricinJ
outViGe of tKe UniteG 6tateV KaV Eeen, anG continueV to Ee, ViJnificantly
leVV
1
Many $merican conVumerV KaYe turneG to CanaGian pKarmacieV aV a
 +erper, supra note 2
 7KomaV +uelVkoetter, State Policies to Address Prescription Drug Prices, C7R FOR $M
3RO*RE66 May 1, 201, 900 $M, KttpVwwwamericanproJreVVorJ
iVVueVKealtKcarereportV201014110VtatepolicieVaGGreVVpreVcriptionGruJpriceV
9. See Prescription Drug Expenditure in the U.S. 1960-2019, 67$7,67$,
KttpVwwwVtatiVtacomVtatiVticV14914preVcriptionGruJe[penGitureVintKeuVVince190




1. See RoEert LanJretK, Drug Prices, BLOOMBER* FeE , 2019, 109 $M,
KttpVwwwEloomEerJcomTuicktakeGruJpriceV illuVtratinJ tKat tKe UniteG 6tateV rankV firVt
in per capita VpenGinJ on preVcription GruJV anG inGicatinJ tKat CanaGa iV not eYen in tKe worlG¶V
top ten
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Vource for tKeir Yitally neeGeG preVcription meGicine, Eut UniteG 6tateV
leJiVlatureV KaYe maGe effortV to preYent tKiV ³EarJain KuntinJ´
14
$ Vimple, yet tellinJ approacK to JauJe tKe effectiYeneVV of a KealtKcare
VyVtem iV to imaJine tKe VyVtem aV a tKreeleJJeG Vtool
1
7Ke firVt leJ
repreVentV Tuality of care, tKe VeconG leJ iV acceVV to care, anG tKe tKirG leJ
iV coVt of care
1
,n orGer to GriYe Gown GruJ priceV anG Ealance tKe Vtool,
tKe Tuality anG acceVV leJV muVt KaYe telemeGicine anG internet pKarmacieV
at tKeir core 7Ke Tuality of UniteG 6tateV KealtKcare KaV Eeen e[tenViYely
Vcrutini]eG Ey tKe Jeneral population witK many criticV Vtill remaininJ, Eut
tKe implementation of new tecKnoloJy KaV receiYeG a poVitiYe reVponVe
from many patientV
1
More anG more patientV now rate tKeir oYerall Tuality
of care conViGeraEly KiJKer tKan in recent yearV
1
6till, tKe µKealtKcare
Vtool¶ EecomeV woEEly wKen many meGical GeYelopmentV are KinGereG or
unGerutili]eG Gue to tKe lack of efficient acceVV to KealtKcare aV a reVult of
³EuGJet conVtraintV´
19
anG inVurance companieV EecominJ leVV likely to
coYer or offer many EenefitV aV tKey once GiG
20
:itK leVV inVurance
coYeraJe, tKe KiJK coVtV of KealtKcare treatment are EeinJ VKifteG to tKe
patient,
21
wKicK createV inVtaEility for tKe tKirG leJ of tKe KealtKcare Vtool
+iJKer KealtKcare coVtV Geter patientV from VeekinJ treatment, anG tKiV
reluctance KaV placeG many rural meGical facilitieV in a poVition wKere tKey
VtruJJle to meet operatinJ coVtV
22
$ poVitiYe aVVeVVment of KealtKcare
Tuality meanV little wKen KiJK coVtV anG limiteG acceVV preYent tKiV Tuality
KealtKcare from EeinJ utili]eG
7Ke UniteG 6tateV iV alVo an outlier amonJ otKer GeYelopeG countrieV
2
in reJarG to GruJ pricinJ, wKicK reVultV in many patientV EecominJ anJereG
Ey continuouVly increaVinJ priceV
24
$ VtuGy comparinJ tKe UniteG 6tateV
14 6teYen MorJan & JeremiaK +urley, Internet Pharmacy: Prices on the Up-and-Up, CM$J
*ROU3 Mar 1, 2004, KttpwwwcmaMcacontent1094full"etoc 
1 $uGiotape RepreVentinJ +oVpitalV, KelG Ey 3rofeVVor 6alYatore J RuVVo Oct 4, 201 on
file witK Brooklyn Law 6cKool
1. Id.
1 RuEen CaVtaneGa, How Technology Helps Patients and Other Visitors Navigate Hospitals,
U6 NE:6 Jan 1, 201, 4 3M, KttpVKealtKuVnewVcomwellneVVarticleV201011Kow
tecKnoloJyKelpVpatientVanGotKerYiVitorVnaYiJateKoVpitalV JuVtin McCartKy, Most
Americans Still Rate Their Healthcare Quite Positively, *$LLU3 'ec , 201,
KttpVnewVJallupcompoll2419americanVrateKealtKcareTuitepoVitiYelyaVp[
1 McCartKy, supra note 1
19 ,N67 OFME', $CCE66 7O+E$L7+C$RE ,N$MER,C$ 1, 19 MicKael Millman eG, 199
20. Id at 19±20
21. Id.
22. Id. at 20
2 $ GeYelopeG country iV ³a country witK a lot of inGuVtrial actiYity anG wKere people
Jenerally KaYe KiJK incomeV´ Developed Country, C$MBR,'*E BU6,NE66 EN*L,6+ ',C7,ON$RY
2011, KttpVGictionarycamEriGJeorJuVGictionaryenJliVKGeYelopeGcountry
24 'ana O 6arnak et al, Paying for Prescription Drugs Around the World: Why Is the U.S.
an Outlier?, 7+E COMMON:E$L7+ FUN' Oct , 201, KttpVwwwcommonwealtKfunGorJ
puElicationViVVueEriefV201octpayinJpreVcriptionGruJVarounGworlGwKyuVoutlier
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montKly pricinJ of Vi[ topVellinJ preVcription GruJV to tKat of otKer
countrieV founG $merican pricinJ to Ee ViJnificantly KiJKer
2
7Ke VtuGy
accountV for tKe ³confiGential GiVcountV´
2
JiYen to UniteG 6tateV KealtKcare
planV, anG tKe Gifference remainV VtaJJerinJ witK Vome GruJV VellinJ for
KunGreGV of GollarV more tKan tKe ne[t pricieVt country
2
$ Veparate VtuGy
alVo VKowV tKat almoVt 1 of inVureG $mericanV fail to take or refill
preVcriptionV Gue to KiJK coVt, compareG to tKe ne[t KiJKeVt country at
10
2
7Ke Vtark GruJ price Gifference Eetween $merica anG otKer countrieV iV
Gue, in part, to tKe few pricecontrollinJ reJulationV, anG in Vome caVeV
reJulationV tKat allow GruJ manufactureV to neJotiate Girectly witK payerV
29
'ruJ manufacturerV tenG to MuVtify tKeir pricinJ Ey linkinJ it to tKe coVt of
³reVearcK, GeYelopment anG manufacturinJ´
0
+oweYer, tKere iV mountinJ
eYiGence VKowinJ tKat tKiV MuVtification iV inaccurate EecauVe tKe true Vource
of tKe KiJK pricinJ iV tKe aEility of GruJ manufacturerV to Vet tKeir priceV aV
KiJK aV tKe UniteG 6tateV market will allow witKout leJiVlatiYe reVtriction or
JuiGance
1
7KiV lack of leJiVlatiYe reVtriction iV larJely Gue to tKe fact tKat
pKarmaceutical manufacturerV KaYe market information at tKeir GiVpoVal tKat
iV unaYailaEle to tKe puElic
2
7KuV, an accurate market price cannot Ee
GiVcerneG, wKicK allowV GruJ manufacturerV to Vet tKeir own, unYerifieG
market price

+oweYer, aV tKiV Note will e[plore, eYen if lawV are enacteG
to manGate GiVcloVure of tKiV market information, price reGuction iV Vtill
unlikely to occur
II PRE9IOU6LY PROPO6E' 6OLUTION6
OYer tKe laVt few GecaGeV, VcKolarV anG leJiVlatorV KaYe propoVeG
VolutionV to tKe GruJ pricinJ iVVue
4
6ome feGeral anG Vtate leJiVlation KaV
2 $merican pricinJ waV  to 11 KiJKer tKan priceV in tKe otKer e[amineG countrieV Id.
2 ConfiGential GiVcountV are neJotiateG priceV Eetween inVurerV, EotK puElic anG priYate, anG
pKarmaceutical manufacturerV 7Ke GiVcountV remain confiGential Vo tKat pKarmaceutical
manufacturerV can cKarJe Gifferent priceV in Gifferent marketV ,nVurerV aEiGe Ey tKiV
confiGentiality in orGer to receiYe Eetter GiVcountV 6teYen * MorJan et al, Payers’ Experiences
with Confidential Pharmaceutical Price Discounts: A Survey of Public and Statutory Health
Systems in North America, Europe, and Australasia, 121 +E$L7+ 3OL¶Y 4, 4± 201
2 6arnak et al, supra note 24
2. Id.
29. Id.
0 $aron Berman et al, Curbing Unfair Drug Prices: A Primer for States, *LOB +E$L7+
JU67 3¶6+,3 $uJ 201, KttpVlawyaleeGuViteVGefaultfileVareacenterJKMp
GocumentVcurEinJBunfairBGruJBpriceVpolicyBpaper001pGf
1. Id.
2. See Lut] +einemann, Biosimilar Insulin and Costs: What Can We Expect?, 102 J OF
',$BE7E6 6C, $N' 7EC+ 4, 4 201
. Id.
4 BenMamin E Brown, Note, Decreasing Prescription Drug Prices: Can Effective Policy
Incentivize Cooperation Between Previously Antithetic Sectors?, 14 ,N' +E$L7+ L REV 12,
1 201
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Eeen enacteG to increaVe competition anG tranVparency amonJ GruJ
manufacturerV, Eut pitfallV witKin VucK lawV anG reJulationV leG to limiteG
VucceVV

7KiV Vection will aGGreVV four preYiouVly propoVeG VolutionV 1
tranVparency reJulationV, 2 cKanJeV to patent lawV,  GruJ importation,
anG 4 manGateG capV on GruJ pricinJ
A TRAN6PARENCYRE*ULATION6
:itK tKe riVinJ coVt of pKarmaceutical GruJ priceV anG tKe increaVeG
meGia coYeraJe, tKirty VtateV,

incluGinJ New York, felt preVVure to
reVponG witK propoVeG leJiVlation

One VucK 2019 Eill, in committee, iV
6enate Bill 6$ New York¶V 3Karmaceutical CoVt 7ranVparency $ct
NY3C7$²reTuirinJ tKe GiVcloVure of tKe coVtV aVVociateG witK GruJ
manufacturinJ

7Ke NY3C7$ applieV to GruJ manufacturerV tKat KaYe ³a
wKoleVale acTuiVition coVt of ten tKouVanG GollarV 10,000 or more
annually´
9
7Ke NY3C7$ reTuireV tKeVe GruJ manufacturerV to GiVcloVe
coVtV for
proGuction reVearcK anG GeYelopment clinical trialV anG otKer reJulatory
coVtV materialV, manufacturinJ anG aGminiVtration coVtV paiG Ey otKer
entitieV, incluGinJ feGeral, Vtate or otKer JoYernmental proJramV otKer
coVtV to acTuire tKe GruJ total marketinJ anG aGYertiVinJ coVtV a
cumulatiYe annual KiVtory of tKe aYeraJe wKoleVale price total profitV
GeriYeG from tKe Vale of tKe GruJ anG tKe total amount of financial
aVViVtance proYiGeG Ey tKe manufacturer, if aYailaEle
40
By manGatinJ GruJ manufacturerV to GiVcloVe tKe aEoYe coVtV, tKe New
York 6enate EelieYeV tKe coVtV of pKarmaceuticalV may Ee rationali]eG or,
more likely, Veen aV unwarranteG EecauVe of tKe GraVtic Gifference Eetween
proGuction anG Vale coVt
41
7ranVparency reJulationV certainly proYiGe EenefitV, Vpecifically tKeVe
reJulationV inGirectly impoVe a reTuirement of morality ,f GruJ
manufacturerV reYeal tKeir pricinJ to Ee JroVVly KiJKer tKan tKe coVtV
reTuireG to ErinJ tKe GruJ to market, tKen Vociety iV likely to Yiew VucK
actionV aV morally wronJ leaGinJ to Vocial puVKEack 7ranVparency
reJulationV alVo VerYe aV a meanV for ³policymakerV, JoYernment aJencieV
. Id. at 1±9
 7reYor Flynn & Jerin 3Kilip, Lowering Drug Costs: Transparency Legislation Sets Off
Flurry of New State Approaches, N$7¶L $C$' FOR 67 +E$L7+ 3OL¶Y $uJ 22, 201,
KttpVnaVKporJlowerinJGruJcoVtVtranVparencyleJiVlationVetVoffflurryofnewVtate
approacKeV
 JoKn * Curran, Note, The New York Pharmaceutical Cost Transparency Act: How a
Narrow View of the Prescription Drug Pricing Puzzle Renders a Well-Intentioned Bill Irrational,
2 BROO. L REV 1, 1 201
. Id.
9 6 $, 201201 ReJ 6eVV NY 201
40. Id.
41 Curran, supra note , at 1±1
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anG otKerV´ to make important puElic Vector GeciVionV,
42
VucK aV VettinJ
price capV on certain preVcription GruJV
4
:Kile tranVparency reJulationV are EackeG witK financially faYoraEle
intentionV, tKiV type of leJiVlation iV VuVceptiEle to pitfallV renGerinJ it
ineffectiYe One VucK pitfall iV tKat leJiVlation, VucK aV tKe NY3C7$,
neJlectV to reTuire GiVcloVure of coVtV aVVociateG witK failure
44
Failure
referV to GruJV tKat neYer make it to market Eut accrue conViGeraEle coVtV
Yet, tKe NY3C7$ GoeV not reTuire GiVcloVure of faileG GruJV EecauVe tKeVe
unVucceVVful GruJV coulG not poVViEly accrue an annual wKoleVale Yalue of
10,000
4
3Karmaceutical companieV are EuVineVVeV, anG like any otKer
EuVineVV, tKey muVt finG a way to recoup tKe loVV of faileG proEeV 7KiV loVV
recoupment coulG Kelp MuVtify KiJKer preVcription coVtV, Eut itV e[cluVion
coulG unGermine tKe ³truVtwortKineVV´ tKat tranVparency leJiVlation VeekV to
proYiGe
4
By failinJ to reTuire tKe GiVcloVure of unVucceVVful GruJV,
leJiVlatureV may inGirectly foVter puElic miVconceptionV aEout GruJ
pricinJ
4
EYen if leJiVlatureV were to remeGy tKiV omiVVion of recoupment
coVtV, tKe tranVparency VtatuteV woulG Vtill proYe ineffectiYe EecauVe mucK
of tKe puElic may conceGe tKat GruJ priceV are reaVonaEle JiYen tKe Euiltin
financial recoupment
$ VeconG, anG poVViEly more ViJnificant, GrawEack of pKarmaceutical
GruJ tranVparency law iV tKat it tenGV to lack enforceaEle penaltieV or any
GiVcipline at all
4
6ome leJiVlatureV KaYe incluGeG penaltieV for e[ceVViYe
³price JouJinJ,´ Eut tKeVe penaltieV KaYe faceG conVtitutional cKallenJeV
49
,n Association for Accessible Medicine v. Frosh,
0
MarylanG¶V
pKarmaceutical tranVparency anG antiprice JouJinJ law reTuireG tKe
GiVcloVure anG MuVtification of coVtV aVVociateG witK tKe proGuction of
preVcription GruJV
1
7Ke law JoeV furtKer tKan merely reTuirinJ GiVcloVure
of coVtV in aGGition to reTuirinJ price MuVtification, a penalty of 10,000 per
Yiolation iV applicaEle if tKe GruJ manufacturer VetV ³an unconVcionaEle
increaVe in tKe price of a preVcription GruJ´
2
7Ke plaintiff in Association
for Accessible Medicine operateG proGuction plantV tKrouJKout tKe UniteG
6tateV, not Volely in MarylanG

7Ke plaintiff arJueG tKat tKe antiJouJinJ
law waV unconVtitutional EecauVe it YiolateG tKe Gormant commerce clauVe
42 6 $
4. See infra 6ection ,,B
44 Curran, supra note , at 2±2
4. Id. at 2
4 6etK :Kitelaw et al, Drug Pricing–The Next Compliance Waterloo, 44 M,7C+ELL
+$ML,NE L REV 11, 119±94 201
4 Curran, supra note , at 2
4 :Kitelaw et al, supra note 4, at 11±
49 $VV¶n for $cceVViEle MeGV Y FroVK,  FG 4,  4tK Cir 201
0. Id. at 4
1. Id. at 
2. Id.
. Id. at 
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of tKe UniteG 6tateV ConVtitution
4
7Ke court KelG tKat MarylanG¶V
tranVparency law waV an attempt to reJulate ³wKolly outofVtate
commerce,´ wKicK iV a power e[preVVly JranteG to tKe FeGeral *oYernment
Yia tKe ConVtitution

7KuV, tKe court founG tKat MarylanG¶V $ct waV
unconVtitutional EecauVe it YiolateG tKe Gormant commerce clauVe aV it
³Girectly reJulateV tranVactionV tKat take place outViGe MarylanG´

:Kile GruJpricinJ tranVparency lawV intenG to preYent tKe VwinGlinJ of
conVumerV, tKiV leJiVlation failV to aGGreVV all circumVtanceV factorinJ into
GruJ pricinJ, VucK aV tKe coVtV of failure $GGitionally, tranVparency
reJulation merely impoVeV a moral EurGen Many attemptV to impoVe
Vtricter, more ViJnificant penaltieV KaYe faceG aEunGant anG VucceVVful
conVtitutional cKallenJeV

B C+AN*E6 TO PATENT LAW
,n tKe realm of pKarmaceutical GruJV, a Yital tool for manufacturerV iV a
GruJ patent EecauVe it proYiGeV two GecaGeV of market e[cluViYity for tKe
patenteG GruJ

7Ke Jeneral iGea EeKinG patent law iV to preYent a ³reVtraint
of traGe´ wKile ³promotinJ fair competition´ Ey precluGinJ otKer
manufacturerV from VtealinJ a company¶V formula anG profitinJ from it, in
aGGition to proYiGinJ protection from anticompetition lawV
9
3Karmaceutical companieV, like any wellrun EuVineVV, look to tKe future
anG anticipate tKe impact of a ³patent cliff´
0
ManufacturerV e[pect a
ViJnificant reGuction in profitV GeriYeG from patenteG GruJV once tKeir
market e[cluViYity enGV
1
EecauVe otKer companieV KaYe tKe opportunity to
uVe tKe formerly patenteG formula for tKeir own profit
2
:itK tKe
e[pectation of reGuceG profitV in tKe future, pKarmaceutical companieV raiVe
tKe price of tKeir GruJV GurinJ tKe patent perioG in orGer to offVet tKiV future
GecreaVe

ConJreVV, in an effort to increaVe pricinJ competition anG partially
circumYent pKarmaceutical GruJ patentV, enacteG tKe 'ruJ 3rice
Competition anG 3atent 7erm ReVtoration $ct, Kereinafter tKe ³+atcK
4. Id. at 
. Id.
. Id. at 4
. See id.
 Brown, supra note 4, at 19
9. Id. at 19±0.
0 ³7Ke perioG of increaVeG preVcription GruJ priceV prior to patent e[piration iV known aV tKe
µpatent cliff¶´ Id. at 19.
1. Id. at 19.
2 'urinJ a patent¶V term, only tKe owner of tKe patent can manufacture tKe inYention or
formula in tKe caVe of pKarmaceuticalV Once e[pireG, tKe patent can Ee copieG anG marketeG Ey
all BeYerly BirG, What Happens to a Patent When it Expires?, LE*$L =OOM,
KttpVinfoleJal]oomcomKappenVpatente[pireV201Ktml laVt YiViteG Oct 10, 2019
 Brown, supra note 4, at 19
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:a[man $ct´
4
7Ke +atcK:a[man $ct iV intenGeG to allow
manufacturerV of a Jeneric ³EioeTuiYalent´ of a nameEranG GruJ to ErinJ
tKe EioeTuiYalent to market prior to tKe e[piration of tKe e[cluViYity
perioG

UnGer tKe +atcK:a[man $ct, manufacturerV of a EioeTuiYalent
complete an aEEreYiateG new GruJ application $N'$ in orGer to Ee
protecteG from patent infrinJement penaltieV

,f tKe application iV
approYeG Ey tKe FooG anG 'ruJ $GminiVtration F'$, a 10Gay Vtay JoeV
into effect tKat preYentV tKe F'$ from approYinJ $N'$V²for tKe
EioeTuiYalent at iVVue²from otKer Jeneric manufacturerV

7Ke +atcK
:a[man $ct facilitateV more GruJpricinJ competition EecauVe a
EioeTuiYalent aYeraJeV 0 cKeaper tKan itV nameEranG counterpart

7Ke +atcK:a[man $ct KaV Eeen VucceVVful in certain aVpectV, Eut it
KaV faileG in one key way it KaV not reGuceG pKarmaceutical priceV 7Ke
+atcK:a[man $ct waV enacteG in 194
9
wKen UniteG 6tateV e[penGiture
on preVcription GruJV waV Eetween twelYe anG forty Eillion GollarV
0
7oGay¶V e[penGiture on preVcription GruJV iV eVtimateG to Ee 0 Eillion,
almoVt nine timeV Jreater tKan tKat of 1901990, anG Vtill more tKan tKree
timeV Jreater wKen accountinJ for inflation
1
$ poVViEle e[planation for tKe
+atcK:a[man $ct¶V ineffectiYeneVV iV tKe pKarmaceutical ta[ unGer tKe
$fforGaEle Care $ct
2
7Ke pKarmaceutical ta[ of tKe $fforGaEle Care $ct
applieV to EranGeG preVcription GruJV, alVo known aV nameEranG GruJV,
wKile e[cluGinJ JenericEranG GruJV

7Ke collecteG ta[ iV tKen funneleG
tKrouJK tKe UniteG 6tateV 7reaVury 'epartment to tKe FeGeral
6upplementary MeGical ,nVurance 7ruVt FunG to Kelp ³Vupport KealtK
inVurance coYeraJe´
4
7KiV pKarmaceutical ta[, in tKeory, woulG allow for more competition
from JenericEranG GruJ manufacturerV, wKile encouraJinJ nameEranG
4 MartKa M Rumore, The Hatch-Waxman Act—25 Years Later: Keeping Pharmaceutical
Scales Balanced, 3+$RM$CY 7,ME6 $uJ 1, 2009,
KttpVwwwpKarmacytimeVcompuElicationVVupplement2009JenericVupplement009Jeneric
KatcKwa[man009
 7Ke term ³EioeTuiYalent´ iV uVeG to GeVcriEe a GruJ tKat iV cKemically tKe Vame aV a name
EranG GruJ 21 U6C   2012
 Rumore, supra note 4, at 1
. Id.
 Brown, supra note 4
9 21 U6C   2012
0 67$7,67$, supra note 9
1. Id.
2 3eter 6 ReicKert], New Taxes for Pharmaceutical and Medical Device




4 $ manufacturer witK an annual aJJreJate reYenue of 100 million woulG pay 10 million
in ta[eV GurinJ tKe firVt year, tKen an increaVinJ ta[ rate eacK year until 2019 $V a manufacturer¶V
aJJreJate reYenue increaVeV, Vo GoeV tKe manufacturer¶V ta[ rate Id.
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GruJ manufacturerV to reGuce coVtV in orGer to aYoiG a KiJKer ta[ rate
NeYertKeleVV, nameEranG manufacturerV KaYe retaineG a larJe conVumer
EaVe tKat iV Vtill willinJ to pay for tKe more e[penViYe GruJ

7KiV
preVerYation of KiJKer GruJ priceV iV larJely Gue to ³aYeraJe ValeV price pluV
Vi[ percent´ or $63

$63 iV tKe meanV Ey wKicK MeGicare payV for
preVcription GruJV

MeGicare will reimEurVe tKe aYeraJe price of tKe
preVcription GruJ pluV Vi[ percent of tKe aYeraJe price ³to coYer oYerKeaG
coVtV´

$63 unintentionally incentiYi]eV tKe preVcription of more
e[penViYe GruJV EecauVe tKe pKyVician will Ee paiG a Jreater oYerKeaG
percentaJe
9
For e[ample, if two EioeTuiYalent GruJV proGuce ³clinically
eTuiYalent EenefitV,´ Eut tKe nameEranG GruJ coVtV 2,000 wKile tKe
JenericEranG coVtV 0, tKen a pKyVician KaV more incentiYe to preVcriEe
tKe nameEranG GruJ
0
,n tKiV e[ample, tKe pKyVician woulG receiYe a 120
profit in oYerKeaG reimEurVement for tKe nameEranG GruJ anG only a 
profit for tKe JenericEranG GruJ
1
,nVteaG of EeinJ uVeG to effectiYely
reGuce preVcription paymentV, tKe $fforGaEle Care $ct¶V pKarmaceutical ta[
iV likely reimEurVinJ coVtV for nameEranG GruJV anG, in turn, neJatinJ tKe
intenGeG EenefitV of tKe ta[
LaVtly, cKanJeV to patent lawV cannot cKanJe nameEranG recoJnition
witK conVumerV
2
3Karmaceutical companieV market to tKeir conVumer EaVe
in a Gifferent manner tKan many otKer inGuVtrieV, Eut, like almoVt all
inGuVtrieV, tKe companieV witK tKe moVt money KaYe tKe moVt name
recoJnition

*enerally, pKarmaceutical companieV Go not promote tKe
company itVelf, ratKer tKey promote a proGuct of tKe company, VucK aV
ViaJra manufactureG Ey 3fi]er
4
7Ke formula for EranG recoJnition iV Tuite
Vimple iGentify an illneVV tKat mucK of tKe population iV VuVceptiEle to,
offer an ³inVert pill name Kere´ aV tKe EeVt remeGy for tKe illneVV, tKen warn
of ViGeeffectV

7Ke GruJ manufacturerV EeKinG ³ElockEuVter GruJV,´ like
ViaJra, can EolVter tKeir remeGy GruJ¶V name tKrouJK more platformV anG
 ,Vaac ' Buck, Note, The Cost of High Prices: Embedding an Ethic of Expense into the
Standard of Care,  BC L REV 101, 129 201




 $63 iV actually tKe aYeraJe ValeV price pluV 4 after a 2012 EuGJet cut, Eut it iV Vtill
referreG to aV $63 7Ke uVe of $63 KaV Eeen e[tenGeG tKrouJK 2024 Id.
9 Buck, supra note , at 12±29
0. Id
1. Id. at 129
2. See 6araK +anG, How Pervasive is Brand Recognition in the Pharmaceutical Industry?,
;7$L.6 Jan 19, 201, KttpV[talkVcomEranGrecoJnitionpKarmaceuticalinGuVtry
. Id.
4. Id. Our Products, 3F,=ER, KttpVwwwpfi]ercomproGuctVproGuctGetailYiaJra laVt
YiViteG Oct 11, 201
 +anG, supra note 2
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witK more freTuency tKan a Jeneric EioeTuiYalent coulG

Ultimately, tKe
pKarmaceutical companieV witK more money anG more EranG recoJnition
will attract more conVumerV tKan Jeneric EioeTuiYalent manufacturerV
C 'RU* IMPORTATION
On aYeraJe, UniteG 6tateV GruJ pricinJ iV tKree timeV more e[penViYe
tKan in foreiJn countrieV EecauVe tKe UniteG 6tateV KaV Veen a Vlow increaVe
in Jeneric GruJ competition compareG to tKe UniteG .inJGom anG Europe
Gue to tKe aforementioneG patent lawV

7KiV price Gifference iV financially
enticinJ to many VtruJJlinJ patientV anG KaV createG a puVK to allow GruJ
importation, Vpecifically from CanaGa Gue to itV pro[imity to tKe UniteG
6tateV

,n 200, tKe MeGicare 3reVcription 'ruJ, ,mproYement, anG
MoGerni]ation $ct MM$ waV ViJneG into law
9
UnGer tKe MM$,
cKeaper GruJV from CanaGa may Ee importeG witK tKe approYal of tKe
+ealtK anG +uman 6erYiceV 6ecretary 6ecretary
90
,n orGer for
importation to receiYe approYal, a VerieV of reTuirementV muVt Ee VatiVfieG,
incluGinJ a certification tKat tKe GruJ to Ee importeG iV cKeaper tKan tKoVe
aYailaEle in tKe UniteG 6tateV anG a Getermination Ey tKe 6ecretary tKat tKe
GruJ poVeV no KealtK riVkV
91
+oweYer, tKe 6ecretary KaV yet to approYe tKe
importation of any GruJ, likely Gue to tKe puVKEack from $merican
pKarmaceutical companieV
92
'eVpite tKe lack of any certification from tKe 6ecretary, Vermont KaV
recently paVVeG leJiVlation allowinJ wKoleVale preVcription GruJ
importation
9
$llowinJ GruJ importation for Vermont citi]enV will
alleYiate a Jreat portion of tKe financial EurGen aVVociateG witK preVcription
GruJV wKile likely creatinJ a pocket of increaVeG GruJ competition witKin
tKe Vtate :Kile fruitful in tKeory, tKe Vermont Vtatute iV almoVt certain to
face feGeral oppoVition anG likely to Ee GefeateG
94
,n Vermont v. Leavitt,
9
Vermont cKallenJeG tKe F'$¶V Genial of tKe Vtate¶V petition to allow
inGiYiGual importation of preVcription GruJV from CanaGa unGer tKe
. Id.
 Ben +irVcKler, How the U.S. Pays 3 Times More for Drugs, REU7ER6 Oct 1, 201,
KttpVwwwreuterVcomarticleuVpKarmaceuticalVuVacompariVone[cluViYetranVatlantic
GiYiGeKowuVpayVtKreetimeVmoreforGruJViGU6.CN061.U2011012
 VaiVKali V 6KaK, Note, Prescription Drugs in America: The Pain of Pricing Has An





9 7KomaV 6ulliYan, Vermont’s Next Act: Wholesale Prescription Drug Importation
Program, 3OL¶Y & ME' May 21, 201, KttpVwwwpolicymeGcom2010YermontVne[t
actwKoleValepreVcriptionGruJimportationproJramKtml
94. Id.
9 Vermont Y LeaYitt, 40 F6upp2G 4, 4 ' Vt 200
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MM$
9
Vermont alVo claimeG tKat tKe MM$ itVelf waV in Yiolation of tKe
UniteG 6tateV ConVtitution EecauVe it JranteG power to tKe E[ecutiYe
BrancK tKat VKoulG KaYe Eeen GeleJateG to tKe LeJiVlatiYe BrancK
9
7Ke
UniteG 6tateV 'iVtrict Court GiVmiVVeG Vermont¶V claimV EecauVe tKe
Vermont petition waV for an illeJal proJram unGer tKe MM$, wKicK allowV
for approYeG ³wKoleVale´ importation, not ³inGiYiGual´ importation
9
RelyinJ on tKiV preceGent, cKallenJeV to tKe Vermont leJiVlation will likely
precluGe tKe importation of preVcription GruJV from CanaGa
$ViGe from leJiVlation, tKere are alVo riVkV tKat will likely preYent GruJ
importation from EecominJ a YiaEle Volution for tKe preVcription pill
financial iVVue One of tKeVe riVkV iV a lack of foreiJn VafeJuarGV aJainVt
poor Tuality anG GanJerouV GruJV EeinJ importeG
99
E[portinJ countrieV
KaYe reJulationV for GruJV purcKaVeG Ey tKeir own citi]enV, Eut Vome, VucK
aV CanaGa, conceGe tKat tKeir reJulationV are not aV Vtrict for tKeir e[porteG
GruJV
100
$GGitionally, many countrieV tKat e[port GruJV, import tKoVe Vame
GruJV from otKer reJionV of tKe worlG
101
7KiV cKain of multiple
importationV not only raiVeV VeriouV reJulatory TueVtionV, Eut alVo increaVeV
tKe proEaEility of GruJ alteration Gue to tKe multiple tranVferV anG
enYironment cKanJeV
102
$n aGGitional riVk aVVociateG witK GruJ
importation iV a KiJKer likeliKooG of counterfeit GruJV
10
CounterfeiterV
KaYe ample reVourceV to recreate laEelV iGentical to nameEranG GruJV, tKat
not only VwinGle patientV out of tKeir money, Eut alVo put patientV in GanJer
of laceG or ineffectiYe GruJV
104
FeGeral reluctance to allow GruJ importation iV not merely EaVeG in
tKeory, Eut it KaV Vupport from caVeV VucK aV 7KaliGomiGe
10
'urinJ tKe
miGtwentietK century, a GruJ known aV 7KaliGomiGe waV GeYelopeG to Kelp
patientV fall aVleep anG eaVe tKe pain of morninJ VickneVV for preJnant
women
10
7KaliGomiGe waV preVcriEeG Tuite freTuently in Europe By
190, it waV eYen VolG oYertKecounter in *ermany, Eut tKe UniteG 6tateV
9. Id. at 49±0
9. Id. at 40
9 7Ke KolGinJ in tKiV caVe KaV not Eeen appealeG, nor KaV it receiYeG neJatiYe treatment Id.
at 49







10 LinGa Bren, Frances Oldham Kelsey: FDA Medical Reviewer Leaves Her Mark on
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waV Vtill reluctant to allow itV uVe
10
7Ke F'$¶V reluctance to allow
7KaliGomiGe waV larJely Gue to tKe VuVpicionV of F'$ MeGical ReYiewer,
FranceV OlGKam .elVey
10
Fortunately for many $mericanV, .elVey waV
proYen correct wKen a report reYealeG tKat more tKan 10,000 cKilGren acroVV
fortyVeYen countrieV were Eorn witK GeformitieV Gue to 7KaliGomiGe uVe Ey
tKeir motKerV
109
,f 7KaliGomiGe or a Vimilar GefectiYe GruJ waV importeG to
tKe UniteG 6tateV, tKe KealtK anG financial effectV woulG Ee GeYaVtatinJ
,mportinJ preVcription GruJV from otKer countrieV woulG certainly
GecreaVe tKe financial EurGen for many $merican patientV +oweYer, in
weiJKinJ tKe financial EenefitV aJainVt tKe riVkV of importinJ poVViEly
counterfeit anG GefectiYe GruJV, tKe Vcale iV GiVproportionally tippeG aJainVt
GruJ importation
' MAN'ATE'CAP6 ON PRE6CRIPTION'RU* PRICE6
LaVtly, VolutionV KaYe Eeen propoVeG tKat woulG allow feGeral or Vtate
leJiVlatureV to enact lawV tKat place a cap on tKe price pKarmaceutical
manufacturerV can cKarJe for tKeir proGuctV
110
7KeVe price cap propoValV
VuJJeVt YaluatinJ preVcription GruJV accorGinJ to accepteG VtanGarGV, anG
otKer computaEle meaVureV in orGer to GeGuce a fair price cap
111
6ome
price cappinJ VolutionV woulG allow EuyerV, VucK aV pKarmacieV, to
comEine tKeir ³purcKaVinJ power´ anG neJotiate aV a VinJle Jroup in orGer
to enforce a price cap
112
7Ke application of price capV coulG VaYe patientV
tenV of tKouVanGV of GollarV per year, wKile VaYinJ tKe feGeral JoYernment
EillionV of GollarV annually
11
3Karmaceutical companieV aGamantly oppoVe price cappinJ for many
reaVonV, mainly EecauVe price cappinJ neJatiYely impactV innoYation
114
:Kile manufacturerV coulG reGuce priceV if tKey only proGuceG a Vet
numEer of GruJV, pKarmaceutical companieV arJue tKat larJe VumV of
money are neeGeG to innoYate, anG tKe only way to acTuire tKe money
neeGeG to innoYate iV Ey maintaininJ tKe current pricinJ VyVtem
11
$GGitionally, pKarmaceutical companieV arJue tKat tKe innoYatiYe proceVV
10. Id.
10. Id.
109 Only VeYenteen $merican cKilGren e[perienceG EirtKGefectV aV a reVult of 7KaliGomiGe
Id.
110. See E]ekiel J Emanuel, The Solution to Drug Prices, NY 7,ME6 6ept 9, 201,
KttpVwwwnytimeVcom2010909opiniontKeVolutiontoGruJpriceVKtml
111. Id.
112. Id. Emily . :Kite, Killing U.S. Slowly: Curing the Epidemic Rise of Cancer Drug
Prices, 2 FOO' $N''RU* L J 19, 214±1 201
11 Emanuel, supra note 110
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inYolYeV failureV,
11
makinJ tKe price of innoYation eYen Jreater tKan many
anticipate
11
7KoVe wKo Vupport a free market arJue tKat price cappinJ anG
increaVeG JoYernment reJulation may only make tKe proElem worVe,
11
poVViEly e[panGinJ tKe iVVue outViGe of tKe KealtKcare anG financial realm
,n aGGition, price cappinJ woulG likely KaYe to take place at tKe feGeral
leYel in orGer to aYoiG Yiolation of tKe commerce clauVe of tKe UniteG 6tateV
ConVtitution
119
7Ke power to reJulate foreiJn anG interVtate commerce reVtV
witK tKe feGeral JoYernment
120
anG conYincinJ a maMority of tKe UniteG
6tateV ConJreVV to enact a law reVtrictinJ tKe free market in a free market
VyVtem iV likely Tuite Gifficult UnleVV a GruJ manufacturer operateV anG
VellV witKin tKe EorGerV of a VinJle Vtate, Vtate attemptV to enforce price capV
will likely Ee preempteG Yia tKe commerce clauVe
121
III A NEW 6OLUTION COMBININ* TELEME'ICINE WIT+
INTERNET P+ARMACIE6
ComEininJ telemeGicine witK internet pKarmacieV will increaVe acceVV
to Tuality meGical opinionV anG treatment, wKicK, in turn, will GriYe Gown
tKe price of preVcription GruJV 'ruJ priceV will GecreaVe EecauVe tKiV
comEination will proYiGe Jreater acceVV to cKeaper, yet effectiYe
preVcription GruJV for tKoVe VtruJJlinJ to meet tKe financial EurGenV of tKeir
meGical treatment 7KiV Volution will Vet a EaVe for increaVeG market
competition tKat promoteV innoYation oYer profit Before GelYinJ into tKe
relationVKip Eetween telemeGicine anG internet pKarmacieV, it iV important
to unGerVtanG tKe concept EeKinG eacK
A TELEME'ICINETELE+EALT+
$V currently implementeG, telemeGicine allowV KomeriGGen patientV
anG patientV witKout local meGical facilitieV to receiYe meGical opinionV
remotely Yia tKe internet
122
+ealtK VerYiceV are facilitateG tKrouJK YiGeo
conferenceV, pKone callV, anG tKe emailinJ of meGical recorGV anG otKer
neceVVary information
12
,n aGGition to information VKarinJ, telemeGicine
proYiGeV neceVVary monitorinJ eTuipment tKat will proYiGe pKyVicianV witK
11. See supra noteV 44±4 anG accompanyinJ te[t
11 Curran, supra note , at 2±2
11 Jennifer BoeGer, Should the Government Cap Prescription Drug Prices?, 7YL7,
KttpVtKetyltcompoliticVJoYernmentcapperVcriptionGruJpriceV laVt YiViteG Oct 24, 2019
119 U6 CON67 art ,,  , cl 
120. The Commerce Clause as a Restraint on State Powers, LE*$L ,NFO ,N67,
KttpVwwwlawcornelleGuconVtitutionconanarticle1VectionclauVetKecommerceclauVe
aVareVtraintonVtatepowerV laVt YiViteG Oct 1, 201
121. Id.
122 .imEerly LoYett Rockwell, The Promise of Telemedicine: Current Landscape and Future
Direction, 9 M,C+ BJ  201
12. Id.
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feeGEack eYen if Girect communication iV not feaViEle
124
7elemeGicine iV an
e[panGinJ market anG iV e[pecteG to Ee wortK 1 Eillion in 2020, a 12
Eillion increaVe from tKe 2014 market Yalue
12
7KiV financial JrowtK Vpurt
iV a reVult of, not only tecKnoloJical aGYanceV, Eut tKe proVpect of a JrowinJ
conVumer EaVe
12
+oVpitalV anG inVurance companieV can now VerYe
populationV tKat KaYe preYiouVly Eeen KinGereG from receiYinJ tKe EenefitV
of clinicV anG KealtK coYeraJe
12
:Ken tKe application of telemeGicine waV introGuceG GurinJ tKe 1990V,
reacKinJ remotely locateG patientV anG proYiGinJ acceVV waV tKe main
focuV, Eut it Eecame apparent tKat telemeGicine coulG reGuce KealtKcare
coVtV aV well
12
7elemeGicine VaYinJV are not limiteG to remotely locateG
patientV, Eut it can Ee e[perienceG Ey moVt of tKe worlG, aV it iV eVtimateG
tKat ³>90@ of tKe worlG population >will@ KaYe a VmartpKone Ey 2020´
129
,n tKe UniteG 6tateV alone, 9 of aGultV own any type of cellpKone anG
1 own a VmartpKone
10
7KeVe ownerVKip percentaJeV KaYe Eeen
conViVtently trenGinJ upwarGV alonJ witK an upwarG trenG in VmartpKone





aVVociateG witK telemeGicine anG tKe potential for more
tKan tKreeTuarterV of $merican aGultV to utili]e telemeGicine VerYiceV make
it a fittinJ matcK for an online pKarmacy²a EuVineVV EaVeG on wireleVV
connectiYity
B INTERNETONLINE P+ARMACIE6
*enerally, internet pKarmacieV operate in a Vimilar manner to tKat of a
pKyVical pKarmacy
1
Once tKe internet pKarmacy receiYeV an official
preVcription from a pKyVician, tKe company VKipV tKe pKarmaceuticalV to tKe
patient, tKuV VaYinJ tKe patient tKe KaVVle of traYelinJ to anG from tKe
pKarmacy
14
:Kile tKiV form of online pKarmacy may Ee tKe moVt
common, it iV one of tKree acknowleGJeG cateJorieV of online
124. Id. at 9
12. Id. at 




129 LoYett Rockwell, supra note 122, at 9
10. Mobile Fact Sheet, 3E: RE6E$RC+ C7R June 12, 2019,
KttpwwwpewinternetorJfactVKeetmoEile
11 ,n tKiV VtuGy, cellpKone GepenGency waV GetermineG Ey tKe amount of VmartpKone uVerV
tKat Go not KaYe a ³traGitional Kome EroaGEanG VerYice´ Id.
12 'orVey & 7opol, supra note 12, at 1
1. See 6KaK, supra note , at  e[plaininJ tKat tKe Joal of many online pKarmacieV iV to
accept anG GiVpenVe YaliG preVcriptionV, MuVt like traGitional pKarmacieV, in a more conYenient
faVKion
14. See 7riVKa 7orrey, How to Safely and Legally Buy Drugs from Online Pharmacies,
VERY:ELL+E$L7+ 6ept , 2019, KttpVwwwYerywellKealtKcomVafelyanGleJallyEuyinJ
GruJVfromonlinepKarmacieV210
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pKarmacieV
1
$ VeconG cateJory of online pKarmacy proYiGeV ³online
conVultation´ in wKicK patientV merely VuEmit a TueVtionnaireVtyle form to
Ee reYieweG Ey a pKyVician wKo tKen GeciGeV wKetKer to preVcriEe
meGicine
1
7KiV VeconG cateJory of online pKarmacy may Veem Vimilar to
tKiV Note¶V Volution, Eut notaEly, cateJory two pKarmacieV Go not inYolYe
facetoface contact anG KaYe Eeen all Eut eliminateG EecauVe of tKe
illeJitimate preVcription of GruJV EaVeG Volely on an online TueVtionnaire
1
$GGitionally, proVecutionV aJainVt ³cateJory two´ online pKarmacieV KaYe
Eeen Vo VucceVVful tKat, in 200, ³ConJreVV amenGeG tKe ControlleG
6uEVtance $ct«to e[plicitly proKiEit GiVpenVinJ anG GiVtriEutinJ controlleG
VuEVtanceV EaVeG Volely on an online TueVtionnaire´
1
LaVtly, tKe tKirG
cateJory of internet pKarmacy iV known aV ³roJue internet pKarmacieV,´
wKicK Vell preVcription GruJV to anyone, eYen tKoVe witKout preVcriptionV
19
RoJue internet pKarmacieV operate ³in Girect Yiolation of feGeral anG Vtate
law,´ anG eYen ³Vell GruJV tKe FooG anG 'ruJ $GminiVtration EanV´
140
Not
only will online pKarmacieV proYiGe cKeaper pKarmaceutical priceV wKen
comEineG witK telemeGicine, tKe facetoface aVpect of teleKealtK will Kelp
acKieYe tKe mucKGeVireG GecreaVe of feGerally ³illicit´ roJue internet
pKarmacieV
141
C W+YONLINE P+ARMACIE6 AN' TELEME'ICINEARE A
PERFECT µPARE¶ FOR'RU* PRICE6
$V of MarcK 2019, tKe UniteG 6tateV KaG 2929 million internet
uVerV
142
7Ke current eVtimateG population of tKe UniteG 6tateV iV 29
million people,
14
meaninJ tKat more tKan  of $mericanV are internet
uVerV $GGitionally, aV of 201, 9 of internetuVinJ aGultV VKop online,
witK 2 of internetuVinJ aGultV VKoppinJ online Yia tKeir moEile
1 BetKany Lipman, Note, Prescribing Medicine for Online Pharmacies: An Assessment of
the Law and a Proposal to Combat Illegal Drug Outlets, 0 $M CR,M L REV 4, 49±0
201
1. Id. at 0
1. Id. at .
1. Id. at 0.
19. Id.
140. Id.
141. The Internet Pharmacy Market in 2016, C7R FOR 6$FE ,N7ERNE7 3+$RM$C,E6 1, 2 Jan
201, KttpVafemeGVonlineorJwpcontentuploaGV201017Ke,nternet3KarmacyMarketin
201pGf
142. Countries with the Highest Number of Internet Users 2019, 67$7,67$,
KttpVwwwVtatiVtacomVtatiVticV229
numEerofinternetuVerVinVelecteGcountrieV laVt YiViteG Oct 24, 2019
14. Total Population of the United States 2024, 67$7,67$,
KttpVwwwVtatiVtacomVtatiVticV22totalpopulationoftKeuniteGVtateV laVt YiViteG Oct
24, 2019
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GeYice
144
7Ke JrowtK of online VKoppinJ KaV outpaceG ErickanGmortar
VKoppinJ Ey 1 Eillion aV illuVtrateG Ey online VKoppinJ¶V JrowtK of 24
Eillion in 201 anG ErickanGmortar¶V JrowtK of only 19 million
14
7KeVe VtatiVticV inGicate a YaVt maMority of tKe UniteG 6tateV¶ population
KaYe online acceVV anG are more likely to enJaJe in online purcKaVeV aV
oppoVeG to ErickanGmortar purcKaVeV FurtKermore, VtatiVticV VKow tKat
many internetuVinJ $mericanV prefer to VKop online, aV oppoVeG to in
Vtore, for tKe Vake of conYenience anG pricinJ
14
:itK Vo many people
connecteG anG VKoppinJ GiJitally, comEininJ telemeGicine anG internet
pKarmacieV createV an e[cellent platform for patientV to wireleVVly connect
to pKyVicianV, wKile VaYinJ tKe trip to tKe ErickanGmortar pKarmacy Ey
purcKaVinJ tKeir preVcription GruJV online
,n aGGition to a noticeaEle increaVe in moEile GeYice uVe, $mericanV
KaYe emEraceG tKe uVe of moEile KealtK applicationV, or m+ealtK
14
7Ke
current eVtimateG market Vi]e for m+ealtK iV 14 Eillion witK itV fiYeyear
proMection liVteG at  Eillion
14
7KeVe fiJureV repreVent MuVt a portion of
tKe GiJital KealtK market wKicK incluGeV m+ealtK, GiJital KealtK VyVtemV,
KealtK analyticV, anG teleKealtK
149
ComEineG, tKe entire UniteG 6tateV
GiJital KealtK market iV eVtimateG to Ee 44 Eillion witK itV proMecteG 2024
Yaluation at 1 Eillion
10
7KiV proMecteG JrowtK in Yalue inGicateV tKat
teleKealtK anG GiJital KealtK uVe will continue to Jrow aV moEile GeYice uVe
increaVeV
11
ConYenient acceVV to preVcription GruJV iV one aVpect of tKe teleKealtK
anG online pKarmacy comEination, Eut tKe main Joal of reGucinJ GruJ coVtV
will Ee acKieYeG tKrouJK tKe preVcription anG marketinJ of cKeaper GruJV
tKrouJK tKe telemeGicine anG internet pKarmacy platform UnGer tKiV
propoVeG Volution, a teleKealtK company woulG enter into a contractual
144. U.S. Online Shopping Reach as of December 2017, by Device, 67$7,67$,
KttpVwwwVtatiVtacomVtatiVticV09uVonlineuVerVVKoppinJreacKEyGeYice laVt YiViteG
Oct 24, 2019
14. Growth of Grocery Sales for E-commerce and Brick-and-Mortar in U.S. 2017, 67$7,67$,
KttpVwwwVtatiVtacomVtatiVticV4JroceryValeVJrowtKecommerceErickanGmortaruV
laVt YiViteG Oct 24, 2019
14 2 of $merican internet uVerV orGer online for tKe Vake of pricinJ anG conYenience aV
compareG to 1 of $merican internet uVerV tKat rarelyneYer make online purcKaVeV U.S. Online
User Primary Reasons to Make Online Purchases 2018, 67$7,67$,
KttpVwwwVtatiVtacomVtatiVticV2primaryreaVonVinternetuVerVmakeGiJitalpurcKaVeV
laVt YiViteG Oct 24, 2019
14. U.S. Digital Health Market Size by Technology Forecast 2014-2024, 67$7,67$,
KttpVwwwVtatiVtacomVtatiVticV994GiJitalKealtKmarketVi]eforecaVtuniteGVtateVEy




11. mHealth Market Worth $23 Billion in 2017 and Estimated to Grow at a CAGR of More
than 35% Over the Next Three Years, REU7ER6 $pr 1, 201,
KttpVwwwreuterVcomEranGfeatureVYenturecapitalarticle"iG 440
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partnerVKip witK an online pKarmacy 7KiV partnerVKip woulG reTuire tKe
teleKealtK pKyVicianV to conVult anG GiaJnoVe patientV Yia YiGeo
conferenceV, aV tKey uVually Go, Eut it woulG alVo reTuire tKe pKyVician to
uVe KiV or Ker EeVt effort to preVcriEe lower coVt GruJV from tKe partnereG
internet pKarmacy¶V Vtore 7Ke profeVVional VerYiceV, proYiGeG Ey tKe
teleKealtK pKyVician, woulG Ee reimEurVeG tKrouJK accepteG inVurance VucK
aV MeGicare, MeGicaiG, anG priYate inVurance companieV
12
3reVcription
GruJ coVtV coulG Ee paiG in tKe Vame manner aV tKe aforementioneG
profeVVional VerYiceV
1
or outofpocket Yia an online payment VyVtem 7Ke
partnerVKip woulG alVo proYiGe ValarieV²paiG out of tKe comEineG reYenue
from tKe telemeGicine anG online pKarmacieV VerYiceV²for tKe teleKealtK
pKyVicianV in e[cKanJe for tKe pKyVicianV¶ loyalty to tKe partnerVKip 7KiV
Valary woulG Ee calculateG EaVeG on fair anG reaVonaEle market VtanGarGV
witK no EonuV incentiYeV EaVeG on tKe EranG or price of tKe GruJV preVcriEeG
aV to aYoiG Vtatutory YiolationV
14
7Ke pKyVicianV will Ee reVponViEle for
perVonally enterinJ tKeir preVcriptionV into tKe online pKarmacy VyVtem,
wKicK will tKen allow tKe preVcription to Ee GiVpenVeG 7KiV reVponViEility
will proYiGe conYenience for patientV, Eut more importantly, it will preYent
falVifieG preVcriptionV from enterinJ tKe VyVtem anG aYoiG tKe creation of a
³roJue internet pKarmacy´
1
7Ke online pKarmacy portion of tKe
partnerVKip will, of courVe, maintain an inYentory of nameEranG GruJV for
VituationV wKere tKe nameEranG GruJ iV tKe only aYailaEle pKarmaceutical
on tKe market to treat certain ailmentV, or if tKe nameEranG manufacturer
KaV market e[cluViYity Yia patent
1
7Ke 7elemeGicineOnline 3Karmacy partnerVKip will Ee aEle to profit
tKrouJK GealV witK JenericEranG manufacturerV *enericEranG
manufactureV are likely to Ee fonG of tKe iGea tKat tKe propoVeG partnerVKip
Vpecifically promoteV JenericEranG GruJV :itK tKe knowleGJe of tKiV
promotional VcKeme, JenericEranG manufactureV will likely Ee more
willinJ to neJotiate a cKeaper price for tKe partnerVKip wKen tKe partnerVKip
orGerV in Eulk 7KiV will make tKe alreaGy cKeaper JenericEranG GruJV
1
eYen more afforGaEle for financially VtruJJlinJ patientV, wKile allowinJ tKe
7elemeGicineOnline 3Karmacy partnerVKip to profit
12 JameV RolanG, 17 Best Telemedicine Companies, +E$L7+L,NE Oct 2, 201,
KttpVwwwKealtKlinecomKealtKEeVttelemeGicinecompanieV1
1. Id.
14. See infra 6ection ,V$
1 Lipman, supra note 1, at 0
1 Brown, supra note 4, at 19
1. Id. at 1
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I9 LE*AL ANALY6I6 OF T+E TELEME'ICINEONLINE
P+ARMACY 6OLUTION
A ANTIKICKBACK 6TATUTE AN' 6TARK LAW
7Ke $nti.ickEack Vtatute
1
waV enacteG to preYent pKyVician
³remuneration´
19
For e[ample, if a pKarmaceutical company offereG a
pKyVician money, VportV ticketV, Kotel VtayV, or otKer formV of payment in
e[cKanJe for tKe pKyVician¶V promiVe to preVcriEe tKe company¶V GruJ to





iV GeViJneG to preYent pKyVicianV from
referrinJ tKeir MeGicare anG MeGicaiG patientV to ³entitieV witK wKicK tKe
pKyVician or an immeGiate family memEer KaV a financial relationVKip´
12
6tark Law iV typically implicateG wKen a referrinJ pKyVician KaV an
ownerVKip Vtake in a GeViJnateG KealtK VerYice VucK aV a clinical laEoratory
or a preVcription GruJ proYiGer
1
On itV face, it may Veem aV tKouJK tKe 7elemeGicineOnline 3Karmacy
partnerVKip createV a Vituation in wKicK tKe $nti.ickEack 6tatute anG 6tark
Law may eaVily Ee YiolateG UnGer tKe $nti.ickEack 6tatute, if a
pKyVician ³knowinJly anG willfully VolicitV or receiYeV any
remuneration«Girectly or inGirectly,´ Ke or VKe iV criminally liaEle
14
3KyVicianV workinJ witK tKe 7elemeGicineOnline 3Karmacy knowinJly
anG willfully accept remuneration, Yia Valary, for tKeir preVcription of
pKarmaceuticalV liVteG on tKe partnerVKip¶V weE Vtore $GGitionally, tKe
pKyVicianV ValarieV from tKe 7elemeGicineOnline 3Karmacy eVtaEliVK a
³financial relationVKip´
1
UnGer 6tark Law, wKere a financial relationVKip
e[iVtV, a pKyVician may not make a referral to tKe entity witK wKicK Ke or
VKe KaV tKe relationVKip
1
+oweYer, tKe 7elemeGicineOnline 3Karmacy
woulG not Yiolate tKeVe lawV EecauVe tKey incluGe e[cluVionV anG ³Vafe
KarEorV´ tKat proYiGe a leJal anG YiaEle plan for tKe partnerVKip to follow
1
,n orGer to fall witKin an $nti.ickEack 6tatute Vafe KarEor, tKe
7elemeGicineOnline 3Karmacy muVt Graft ³perVonal VerYiceV anG
1 $nti.ickEack 6tatute, 42 U6C  120aE 2019
19 Remuneration iV payment, or Vome form of conViGeration, in e[cKanJe for a VerYice A
Roadmap for New Physicians: Fraud and Abuse Laws, U6 'E3¶7 OF +E$L7+ $N' +UM$N
6ERV6 201, KttpVoiJKKVJoYcompliancepKyVicianeGucation01lawVaVp
10. Id.
11 6tark Law iV alVo known aV 3KyVician 6elfReferral Law or 42 U6C  19nn Physician
Self Referral, C7R6 FOR ME',C$RE & ME',C$,' 6ERV6 Jan , 201, 109 $M,
KttpVwwwcmVJoYMeGicareFrauGanG$EuVe3KyVician6elfReferralinGe[Ktml
12 U6 'E3¶7 OF+E$L7+ $N'+UM$N 6ERV6, supra note 19
1. See id.
14 42 U6C  120aE1 2019
1 42 U6C  19nna 2019
1. Id.
1 U6 'E3¶7 OF+E$L7+ $N'+UM$N 6ERV6, supra note 19
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manaJement contractV´
1
Eetween tKe online pKarmacy anG tKe pKyVicianV
7KeVe contractV muVt incluGe VeYen coGifieG elementV in orGer to VatiVfy tKe
e[cluVion
19
7Ke aJreement muVt 1 Ee in writinJ, 2 incluGe tKe VerYiceV
to Ee proYiGeG Ey EotK partieV,  Vpecify tKe lenJtK of VerYice, if not full
time, 4 KaYe a term lonJer tKan one year,  in aGYance, Vet an aJJreJate
compenVation tKat conformV to fair market Yalue
10
anG GoeV not conViGer
³tKe Yolume or Yalue of any referralV,´  not promote any EuVineVV
practice in Yiolation of Vtate or feGeral law, anG  Vpecify tKat tKe
aJJreJate VerYiceV EeinJ aJreeG to are reaVonaEly neceVVary to run tKe
EuVineVV in a MuVtifiaEle manner
11
7Ke firVt four reTuirementV are Tuite
clearcut anG, in tKiV propoVeG Volution, are likely VatiVfieG witK eaVe 7Ke
fiftK reTuirement callV for tKe 7elemeGicineOnline 3Karmacy to GiliJently
calculate fair market compenVation UnGer tKiV calculation, tKe partnerVKip
muVt enVure tKat itV pKyVicianV¶ compenVation Ee comparaEle to tKat of
otKer pKyVicianV performinJ tKe Vame ³type, Tuality, anG Tuantity´ of
VerYiceV
12
7o VatiVfy tKe Vi[tK reTuirement, tKe partnerVKip muVt KaYe
Vpecific cKeckV anG EalanceV in place to aYoiG YiolatinJ Vtate anG feGeral
lawV One VucK cKeck coulG Ee a KirinJ an outViGe lawyer or inKouVe
counVel taVkeG witK, amonJ otKer tKinJV, enVurinJ tKe EuVineVV¶V oEMectiYeV
are in compliance witK Vtate anG feGeral lawV
1
$notKer Vimilar cKeck
coulG Ee tKe eVtaEliVKment of a compliance Gepartment, wKicK, in aGGition
to enVurinJ compliance witK Vtate anG feGeral lawV, woulG enVure
conformity witK acceptaEle profeVVional, internal, anG EuVineVV VtanGarGV
14
LaVtly, tKe VeYentK reTuirement can Ee VatiVfieG Ey contractinJ only for
VerYiceV GeemeG neceVVary to tKe operation of tKe 7elemeGicineOnline
3Karmacy 7KeVe VerYiceV are likely to incluGe tKe reJular actiYitieV tKat
telemeGicine companieV anG online pKarmacieV perform inGiYiGually, in
aGGition to tKe referralV witKin tKe partnerVKip
7Ke 7elemeGicineOnline 3Karmacy¶V contracteG pKyVicianV coulG Ee
Veen aV employeeV, tKuV raiVinJ furtKer iVVueV of poVViEle $nti.ickEack
6tatute YiolationV +oweYer, tKe Vafe KarEorV of tKe Vtatute incluGe
1 42 CFR  100192G 2019
19. Id.
10 ³Fair market Yalue meanV tKe Yalue in arm¶VlenJtK tranVactionV, conViVtent witK tKe
Jeneral market Yalue µ*eneral market Yalue¶ meanV tKe price tKat an aVVet woulG ErinJ aV tKe
reVult of bone fide EarJaininJ Eetween wellinformeG EuyerV anG VellerV wKo are not otKerwiVe in
a poVition to Jenerate EuVineVV for tKe otKer party´ 42 CFR  4111 2019
11 42 CFR  100192G 2019
12 42 CFR  4111 2019
1 3erYin R 7aleyarkKan, The Attorneys on the Inside: Functions and Goals of In-House
Legal Counsel, $B$ $uJ 9, 201,
KttpVwwwamericanEarorJJroupVyounJBlawyerVpuElicationVtyltopicVinKouVe
counVelattorneyVinViGefunctionVJoalVinKouVeleJalcounVel
14. The Role of A Compliance Officer, ROBER7 :$L7ER6 2019, KttpVwwwroEertwalterV
uVacomcareeraGYicetKeroleofacomplianceofficerKtml
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employeeV in a ³Eone fiGe employment relationVKip witK tKe employer´
1
7Kerefore, if tKe pKyVicianV unGer tKe partnerVKip are GeemeG to Ee
employeeV, aV oppoVeG to contractorV for perVonal VerYiceV anG
manaJement, tKen tKe 7elemeGicineOnline 3Karmacy will Vtill fall witKin
an $nti.ickEack 6tatute Vafe KarEor
6tark Law proKiEitV pKyVicianV from referrinJ patientV to a GeViJnateG
KealtK VerYiceV
1
entity witK wKicK tKe pKyVician KaV a ³financial
relationVKip´
1
$ financial relationVKip incluGeV a compenVation
aJreement,
1
aV woulG Ee preVent in tKe 7elemeGicineOnline 3Karmacy
partnerVKip +oweYer, like tKe $nti.ickEack 6tatute, 6tark Law proYiGeV
e[ceptionV for Eone fiGe employment relationVKipV anG perVonal VerYice
arranJementV
19
,f tKe relationVKip Eetween tKe pKyVicianV anG tKe online
pKarmacy iV GeemeG to Ee tKat of employment, tKen tKree conGitionV muVt
Ee met 1 tKe VerYiceV performeG muVt Ee iGentifiaEle, 2 tKe amount of
remuneration muVt Ee conViVtent witK fair market Yalue anG not take into
account tKe amount anG Yalue of any referralV, anG  tKe compenVation
proYiGeG muVt Ee conViGereG reaVonaEle eYen if no referralV are maGe
10
6tark Law applieV a Vtrict liaEility VtanGarG, wKicK meanV tKere iV no
reTuirement of a menV rea
11
to eVtaEliVK a Yiolation
12
7Ke Vtrict liaEility
VtanGarG may Veem to increaVe tKe riVk of noncompliance +oweYer, tKe
tKree conGitionV, Vet fortK in tKe Vtatute, are eaVily met if one iV to look Eack
to tKe $nti.ickEack Vafe KarEorV 7Ke reTuirementV for tKe 6tark Law
e[cluVion are alVo coYereG Yia tKe $nti.ickEack e[cluVionV 7Ke
7elemeGicineOnline 3Karmacy muVt iGentify tKe reVponViEilitieV of tKe
pKyVicianV, calculate tKe pKyVicianV¶ ValarieV EaVeG on fair market VtanGarGV,
anG tKe Valary muVt Ee conViGereG reaVonaEle anG not account for referralV
maGe 7KuV, if tKe 7elemeGicineOnline 3Karmacy fallV witKin tKe
aforementioneG $nti.ickEack Vafe KarEorV, tKen tKe partnerVKip iV likely to
aYoiG a Yiolation of 6tark Law aV well
,f, on tKe otKer KanG, tKe pKyVician¶V relationVKip witK tKe online
pKarmacy more cloVely reVemEleV a perVonal VerYice arranJement, tKen Vi[
conGitionV, unGer 6tark Law, muVt Ee met 1 tKe arranJement muVt Ee in
ViJneG writinJ anG Vpecify VerYiceV to Ee coYereG, 2 tKe arranJement muVt
1 42 CFR  100192i 2019
1 6tark Law VpecifieV ten GeViJnateG KealtK VerYiceV For tKe purpoVe of tKiV note, focuV
VKoulG Ee placeG on tKe nintK GeViJnateG KealtK VerYice outpatient preVcription GruJV 42 CFR 
41111i[ 2019
1 42 U6C  19nna 2019
1. Id. at a2B
19 42 CFR 411c 2011 42 CFR 411G 2019
10. Id. at c
11 ³MenV rea referV to criminal intent´ Mens Rea, LE*$L ,NFO ,N67,
KttpVwwwlawcornelleGuwe[menVBrea laVt YiViteG NoY 20, 201
12 B$RRY R FURRO: E7 $L, +E$L7+ L$: C$6E6, M$7ER,$L6, $N' 3ROBLEM6 10
$EriGJeG tK eG 201
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Vpecifically iGentify tKe VerYiceV furniVKeG Ey tKe pKyVician,  tKe
aJJreJate amount of VerYiceV muVt Ee reaVonaEly neceVVary for tKe
EuVineVV¶V purpoVeV, 4 tKe aJreement Ee no VKorter tKan one year,  tKe
compenVation muVt Ee conViVtent witK fair market Yalue, anG  tKe
VerYiceV proYiGeG Go not Yiolate 6tate or FeGeral law
1
7KeVe conGitionV
are VtrikinJly Vimilar to tKoVe coGifieG in tKe $nti.ickEack Vafe KarEorV
6imilar to an employment relationVKip, if all reTuirementV for perVonal
VerYice arranJementV are met in tKe Vame manner aV tKe $nti.ickEack Vafe
KarEorV, tKen a 6tark Law Yiolation iV likely to Ee aYoiGeG 7Kerefore, if tKe
7elemeGicineOnline 3Karmacy aEiGeV Ey tKe e[cluVionV coGifieG in tKe
$nti.ickEack anG 6tark Law 6tatuteV, tKen tKe partnerVKip will aYert
Vtatutory Yiolation
B +IPAA AN' PRI9ACY I66UE6
7Ke 7elemeGicineOnline 3Karmacy muVt comply witK tKe reJulationV
of tKe +ealtK ,nVurance anG 3ortaEility anG $ccountaEility $ct +,3$$
EecauVe tKe partnerVKip proYiGeV KealtKcare anG tranVferV KealtK information
Yia an electronic platform
14
BotK pKarmacieV anG teleKealtK companieV are
coYereG entitieV unGer +,3$$,
1
meaninJ tKe telemeGicine company anG
online pKarmacy woulG alreaGy Ee in compliance witK +,3$$ prior to any
formation of a partnerVKip 6till, a poVViEly larJer leJal riVk to KealtK
priYacy iV tKe GanJer of Gata EreacKeV
Many priYacy lawV anG company policieV KaYe Eeen enacteG to protect
conVumer priYacy EotK online anG offline
1
:Kile numerouV, tKeVe lawV
anG policieV Go not coYer all priYacy riVkV, anG many fail to proYiGe proper
notice or unGerVtanGinJ to conVumerV aV to wKat information iV protecteG
1
$GGitionally, witK reVpect to tKe inGiYiGual company policieV, tKe policieV
are more akin to ³corporate GiVclaimerV, ratKer tKan conVumer
JuaranteeV´
1
Many company policieV anG enacteG lawV focuV on tKe
intentional releaVe of Gata,
19
Eut many Veem to neJlect unintentional
releaVeV or Gata EreacKeV 7KiV priYacy riVk woulG Ee of Jreat concern to tKe
patientV of tKe 7elemeGicineOnline 3Karmacy EecauVe tKe patientV woulG
Ee protecteG aJainVt intentional Gata releaVe, Eut tKey woulG Veem to KaYe
no remeGy for unintentional releaVeV Fortunately, an important leJal VKift iV
takinJ place tKat woulG allow for eYen Jreater protection of conVumer anG
1 42 CFR 411G 2019
14 4 CFR  10102a 2019
1 4 CFR  1000 2019
1 LinGVey Barrett, Model(ing) Privacy: Empirical Approaches to Privacy Law &
Governance,  6$N7$ CL$R$+,*+ 7EC+ LJ 1, 10±11 201
1. Id. at 1±1
1. Id. at 1
19. Id. at 10±11
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patient information
190
California recently paVVeG a priYacy law tKat will
allow patientV, aV conVumerV, to Vue for Gata EreacKeV
191
Many otKer VtateV
are likely to follow California¶V e[ample EecauVe tKe ³*olGen 6tate´ KaV
inVpireG otKer lawmakerV witK many of itV proJreVViYe actV
192
7KiV law, if
enacteG tKrouJKout tKe UniteG 6tateV, woulG allow patientV of tKe
7elemeGicineOnline 3Karmacy to recoYer for unintentional releaVeV of
Gata, proYiGinJ an e[tra layer of aVVurance
19
$GGitionally, tKe
7elemeGicineOnline 3Karmacy woulG likely Vee tKiV priYacy law aV an
incentiYe to proYiGe more effectiYe anG numerouV EuttreVVeV aJainVt Gata
leakV, tKuV proYiGinJ Jreater leJal protection for tKe partnerVKip, in aGGition
to proYiGinJ Jreater priYacy protection for itV patientV
194
C LE*AL BARRIER6 AN' T+EREIMBUR6EMENTMO'EL
$n iVVue facinJ tKe propoVeG 7elemeGicineOnline 3Karmacy iV tKe
e[tent to wKicK MeGicare anG MeGicaiG will reimEurVe itV coVtV
19
7KiV
iVVue KaV a Jreater impact on tKoVe uVinJ MeGicare aV a reimEurVement
VyVtem EecauVe MeGicaiG iV Vilent in reJarG to cateJori]inJ teleKealtK aV a
GiVtinct VerYice, anG tKe CenterV for MeGicare anG MeGicaiG 6erYiceV
CM6 promote ³fle[iEility´ in reimEurVinJ teleKealtK tKrouJK MeGicaiG
19
On tKe otKer KanG, CM6 iV more reluctant to reimEurVe teleKealtK
companieV tKrouJK MeGicare for VerYiceV otKer tKan tKoVe uVeG for Girect
communication, VucK aV monitorinJ VyVtemV
19
$GGitionally, limitationV on
reimEurVement KaYe Eeen Vet tKat create an ³eliJiEle patient population   
´
19
7o Ee witKin tKe eliJiEle population, a patient muVt, amonJ otKer
factorV, liYe a certain GiVtance away from meGical facilitieV anG Ee enrolleG





194. Cf. :illiam + :illiamV, Note, On the Clock, Best Bet to Draft Cyberdefensive Linemen:
Federal Regulation of Sports Betting from a Cybersecurity Perspective, 1 BROO. J COR3 F,N
& COM L 9, , 2019 e[plaininJ Kow Gata protection anG cyEerVecurity are JrowinJ anG
important concernV for naVcent inGuVtrieV in tKeir attempt to Jain leJitimacy anG conVumer
confiGence
19 CKarleV 7ownley & RacKel YalowicK, Improving Behavioral Health Access & Integration
Using Telehealth & Teleconsultation: A Health Care System for the 21st Century, N$7¶L $C$'
FOR 67 +E$L7+ 3OL¶Y 1, 4 NoY 201, KttpVnaVKporJwp
contentuploaGV201117elemeGicine1pGf
19 More ³fle[iEility´ iV likely aVVociateG witK MeGicaiG EecauVe VtateV contriEute to tKe
MeGicaiG VyVtem aV oppoVeG to tKe completely FeGeral MeGicare VyVtem 6ince eacK Vtate KaV itV
own reimEurVement VcKeme, fle[iEility iV reTuireG to accommoGate eacK 6tate¶V policy on
telemeGicine reimEurVement See id.
19. Id.
19 Latoya 7KomaV & *ary CapiVtrant, 50 State Telemedicine Gaps Analysis: Coverage &
Reimbursement, $M 7ELEME',C,NE$66¶N 1,  Jan 201
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in tKe correct payment plan
199
7KeVe limitationV woulG compounG tKe
iVVueV facinJ tKe 7elemeGicineOnline 3Karmacy EecauVe many patientV
woulG not receiYe full inVurance coYeraJe, or eYen Tualify for any inVurance
coYeraJe
200
7wentynine VtateV KaYe maGe an attempt to comEat tKe limitationV on
reimEurVement Ey enactinJ lawV reTuirinJ priYate inVurance companieV to
reimEurVe telemeGicine VerYiceV in tKe Vame manner aV VerYiceV proYiGeG Ey
ErickanGmortar pKyVician officeV
201
7elemeGicine companieV KaYe alVo
reVponGeG Ey contractinJ Girectly witK employerV to proYiGe all teleKealtK
VerYiceV for a Vet fee
202
:Kile tKeVe priYate inVurance lawV anG tKe Girect
contractinJ witK employerV improYe tKe teleKealtK reimEurVement VyVtem,
tKey Go not cKanJe MeGicare¶V reluctance to coYer all telemeGicine
VerYiceV
20
7KeVe cKanJeV in Vtate priYate inVurance law anG telemeGicine
employer contractinJ Veem to create an optimiVtic Eelief tKat MeGicare will
eYentually proYiGe reimEurVement for teleKealtK VerYiceV in tKe Vame
manner tKat it GoeV for ErickanGmortar pKyVician officeV Be tKat aV it
may, for tKe time EeinJ, many MeGicare EeneficiarieV may Ee reluctant to
utili]e tKe 7elemeGicineOnline 3Karmacy EecauVe of tKe limitationV on
reimEurVement
9 A COMPARABLE COMPANY RO
One company VucceVVfully uVinJ a EuVineVV moGel Vimilar to tKiV Note¶V
propoVeG Volution iV Ro, an online pKarmacy tKat Vpeciali]eV in erectile
GyVfunction, Kair loVV, premature eMaculation, colG VoreV, anG Jenital KerpeV
for men
204
Ro alVo focuVeV in eyelaVK loVV, Ve[ iVVueV, anG Vleep iVVueV for
women,
20
aV well aV VmokinJ ceVVation for men anG women
20
UnGer tKe
Ro platform, a patient proYiGeV KiV or Ker meGical KiVtory, communicateV
witK a pKyVician Yia online meVVaJinJ or YiGeoconference, tKen, if tKe
pKyVician GeemV acceptaEle, a preVcription iV proYiGeG
20
7Ke Girect
communication anG online preVcriEinJ of meGicine iV Vimilar to tKe
7elemeGicineOnline 3Karmacy¶V moGel, Eut Ro iV, in Vome wayV,
noticeaEly Gifferent from tKiV Note¶V propoVeG Volution 7Ke main
Gifference iV tKat Ro only proYiGeV preVcriptionV for limiteG ailmentV,
20
aV
oppoVeG to tKe YariouV otKer preVcriptionV tKat woulG Ee aYailaEle to
199. Id.
200. See id.
201. Id. at , 29±9.
202 LoYett Rockwell, supra note 122, at 41
20. Id. at 40
204. FAQ, ROM$N, KttpVwwwJetromancomfaT laVt YiViteG 6ept , 2019
20. Frequently Asked Questions, RORY, KttpVwwwKellororycomfaTV laVt YiViteG 6ept ,
2019
20. FAQ, =ERO, KttpVTuitwitK]erocomfaT laVt YiViteG 6ept , 2019
20 ROM$N, supra note 204
20. Id.
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patientV tKrouJK tKe 7elemeGicineOnline 3Karmacy $GGitionally, Ro iV
merely a Vupplement to a patient¶V reJular KealtK plan anG GoeV not VerYe aV
tKe patient¶V primary pKyVician
209
7KiV Note¶V propoVeG Volution woulG
VerYe aV a patient¶V primary care center anG woulG KaYe tKe aEility to
preVcriEe meGication for YariouV ailmentV anG conGitionV, incluGinJ tKoVe
coYereG Ey Ro :Kile Ro performV only a fraction of wKat tKe
7elemeGicineOnline 3Karmacy woulG proYiGe, it iV a Jreat VmallVcale
inGicator of tKe YiaEility anG profitaEility
210
of tKiV Note¶V propoVeG
Volution
CONCLU6ION
$ 7elemeGicineOnline 3Karmacy partnerVKip iV a poVViEle meanV to
GriYe Gown pKarmaceutical GruJV priceV 7Ke partnerVKip woulG proYiGe
Jreater acceVV to KiJKer Tuality KealtK care, wKile improYinJ market
competition amonJ pKarmaceutical companieV 7KiV increaVe in market
competition can Ee acKieYeG tKrouJK 7elemeGicineOnline 3KarmacieV
promotinJ JenericEranG GruJV in orGer to attract all patientV, eVpecially tKe
oneV tKat KaYe Eeen VtruJJlinJ to meet tKe coVt of nameEranG preVcription
GruJV ,f VucceVVful in creatinJ Jreater market competition, tKen
7elemeGicineOnline 3KarmacieV will compel nameEranG pKarmaceutical
companieV to lower tKeir priceV in orGer to compete witK tKe JenericEranG
priceV, anG eYen Ee promoteG tKrouJK telemeGicineonline pKarmacieV, if
priceV are GeemeG afforGaEle $GGitionally, VafeJuarGV aJainVt poorly
manaJeG or illeJal online pKarmacieV will promote tKe uVe of telemeGicine
online pKarmacieV, wKile proYiGinJ patientV witK information aEout tKe
moVt reputaEle weEViteV
211
Not only Go VafeJuarGV, VucK aV tKe Center for
6afe ,nternet 3KarmacieV, proYiGe Yerification for online pKarmacieV, Eut
tKey proGuce reportV anG EloJ upGateV pertaininJ to tKe EeVt anG fair online
pKarmacieV aV well aV tKe worVt, anG likely illeJal
212
,f 7elemeGicine
Online 3KarmacieV can effectiYely naYiJate tKe leJal reTuirementV impoVeG
on KealtKcare companieV
21
anG promote lower priceG pKarmaceuticalV, tKen
financially VtruJJlinJ patientV are likely to receiYe improYeG acceVV to care
anG lower preVcription priceV
209. Id.
210 JoVK ConVtine, Erectile Pharmacy App Roman Raises $88M to Launch ‘Quit Smoking’ Kit,
7EC+ CRUNC+ 6ept 1, 201, KttpVtecKcruncKcom201091roman]eroTuitVmokinJ
notinJ tKat Ro¶V Roman +ealtK for men KaV a ³reYenue runrate in tKe 10V of millionV´ of
GollarV
211. Mission, Goals & Objectives, C7R FOR 6$FE ,N7ERNE7 3+$RM$C,E6,
KttpVVafemeGVonlineorJwKowearemiVVionJoalVoEMectiYeV laVt YiViteG $uJ , 2019
212. Id.
21. See 42 U6C  120aE 2019 42 U6C  19nn 2019
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